

REMARKS

Claims 1-14 are amended herein. Support for the amendments can be found throughout the specification, including paragraphs [0005], [0006], and [0043] of the published application and the claims as originally filed. No new matter has been added. Accordingly, Claims 1-14 remain pending. In view of the amendments and remarks set forth herein, reconsideration is respectfully requested.

Claim Rejections Under 35 U.S.C. §101

Claim 12 is rejected under 35 U.S.C. §101. It is submitted that present Claim 12 meets the requirements of 35 U.S.C. §101. Therefore, reconsideration and withdrawal of the rejection are respectfully requested.

Claim Rejections Under 35 U.S.C. §112

Claims 1-14 are rejected under 35 U.S.C. §112 second paragraph for allegedly being indefinite. Applicants respectfully disagree.

Claim 11 is drawn to a culture medium comprising a region-modified glycan and/or glycosaminoglycan as defined in the claim. The term “culture medium” is well-known term in the art and a skilled person can clearly envisage which embodiments are encompassed in the claim. Although Applicants submit that claim 11 is definite, in an effort to expedite prosecution, the claim is amended to further define components of the culture medium. Applicants submit that the claim is sufficiently clear.

Claims 1-10 and 12-14 are amended to more clearly define the subject-matter. In particular, claim 1 is amended to correct a typographical error replacing “wanted” with “unwanted”. Reconsideration and withdrawal of the rejection under 35 U.S.C. §112 are respectfully requested.

Claim Rejections Under 35 U.S.C. §102(b)

Claim 11 is rejected under 35 U.S.C. §102(b) for allegedly being anticipated by Gupta et al. (Journal of Investigative Medicine, 1995). Applicants disagree with the rejection.

Claim 11 relates to region-modified glycan and/or glycosaminoglycans having specific modifications. These modifications are not disclosed in by Gupta et al. For this reason alone, Gupta et al. fails to anticipate the claim. Additionally, Gupta et al. also does not disclose a culture medium comprising a growth medium, nutrients, and the region-modified glycan and/or glycosaminoglycans as recited in the claims.

A claim is anticipated only if each and every element is described in a single prior art reference. As Gupta et al. fails to teach or suggest each and every element of claim 11, reconsideration and withdrawal of the rejection under 35 U.S.C. § 102(b) is respectfully requested.

Conclusion

Applicants submit that the application is now in proper form for allowance, which action is earnestly solicited. If resolution of any remaining issue is required prior to allowance of the application, it is respectfully requested that the Examiner contact Applicants' attorney at the telephone number provided below.

Respectfully submitted,

/james f. harrington/
James F. Harrington
Registration No.: 44,741
Attorney for Applicants

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550
JFH:jp
366098_1.DOC